[
    [
        {
            "time": "2023-03-15",
            "original_text": "Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study",
            "features": {
                "keywords": [
                    "Olumiant",
                    "Late-Stage",
                    "Eczema",
                    "Succeeds"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "Earnings Miss: Pfizer Inc. Missed EPS By 16% And Analysts Are Revising Their Forecasts",
            "features": {
                "keywords": [
                    "Earnings",
                    "Miss",
                    "Pfizer",
                    "EPS",
                    "Analysts",
                    "Revising"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "LLY",
                    "PFE",
                    "Q4",
                    "Results",
                    "JNJ",
                    "Coronavirus",
                    "Vaccine"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "Bayer Seeks FDA Approval for New Formulation of Nifurtimox",
            "features": {
                "keywords": [
                    "Bayer",
                    "FDA",
                    "Approval",
                    "Nifurtimox",
                    "Formulation"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCEâ„¢ (rituximab)",
            "features": {
                "keywords": [
                    "Pfizer",
                    "CHMP",
                    "Opinion",
                    "Oncology",
                    "Biosimilar",
                    "RUXIENCE"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "Bayer wins EU recommendation for prostate cancer drug",
            "features": {
                "keywords": [
                    "Bayer",
                    "EU",
                    "Recommendation",
                    "Prostate",
                    "Cancer",
                    "Drug"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]